0000939767-20-000125.txt : 20200904
0000939767-20-000125.hdr.sgml : 20200904
20200904183859
ACCESSION NUMBER: 0000939767-20-000125
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200902
FILED AS OF DATE: 20200904
DATE AS OF CHANGE: 20200904
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hessekiel Jeffrey
CENTRAL INDEX KEY: 0001599803
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30235
FILM NUMBER: 201162693
MAIL ADDRESS:
STREET 1: 210 EAST GRAND AVE.
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: EXELIXIS, INC.
CENTRAL INDEX KEY: 0000939767
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
IRS NUMBER: 043257395
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0101
BUSINESS ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
BUSINESS PHONE: 6508377000
MAIL ADDRESS:
STREET 1: 1851 HARBOR BAY PARKWAY
CITY: ALAMEDA
STATE: CA
ZIP: 94502
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS INC
DATE OF NAME CHANGE: 20000207
FORMER COMPANY:
FORMER CONFORMED NAME: EXELIXIS PHARMACEUTICALS INC
DATE OF NAME CHANGE: 20000106
4
1
wf-form4_159925911942541.xml
FORM 4
X0306
4
2020-09-02
0
0000939767
EXELIXIS, INC.
EXEL
0001599803
Hessekiel Jeffrey
C/O EXELIXIS, INC.
1851 HARBOR BAY PARKWAY
ALAMEDA
CA
94502
0
1
0
0
EVP and General Counsel
Common Stock
2020-09-02
4
A
0
4998
0
A
255311
D
Common Stock
2020-09-02
4
F
0
1311
21.58
D
254000
D
Common Stock
999
I
By 401(k)
Represents shares of Exelixis, Inc. common stock issued to the Reporting Person upon vesting of restricted stock units. Each restricted stock unit is the economic equivalent of one share of Exelixis, Inc. common stock.
On September 10, 2018, the Reporting Person was granted a performance-based restricted stock unit ("PSU") award of 4,998 shares of common stock under the Exelixis, Inc. 2017 Equity Incentive Plan. Vesting of the PSU award is tied to performance goals set by the Compensation Committee (the "Committee") as follows: (i) 50% of the original number of shares subject to the award will vest upon the Committee's certification that a target number of potentially label-enabling clinical trials evaluating cabozantinib (both alone or in combination with another therapy) have been initiated; and (ii) 50% of the original number of shares subject to the award will vest on the first quarterly PSU vesting date (i.e. February 15th, May 15th, August 15th and November 15th) following the one-year anniversary of the Committee's certification.
On September 2, 2020, the Committee convened to determine that the target number of clinical trial initiations had been achieved, resulting in the immediate vesting of 50% of the PSU award, and the remaining 50% will vest on November 15, 2021, subject to the Reporting Person's continuous service through that date.
Includes 39,058 shares of Exelixis, Inc. common stock that will be issued to the Reporting Person upon vesting of restricted stock units.
Shares withheld by Exelixis, Inc. to satisfy taxes payable in connection with the vesting of certain restricted stock units earned on September 2, 2020.
Represents shares of Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 1, 2020.
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
2020-09-04